PharmacoEconomics

Acknowledgment

Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK

Á Benedict, L Verdian, G Maclaine

QALYs and Carers

Hareth Al-Janabi, Terry N. Flynn, Joanna Coast

Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease

Judith Dams, Bernhard Bornschein, Jens Peter Reese, Annette Conrads-Frank, Wolfgang H. Oertel, Uwe Siebert, Richard Dodel

Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy

Rumona Dickson, Adrian Bagust, Angela Boland, Michaela Blundell, Helen Davis, Yenal Dundar, Juliet Hockenhull, Carlos Martin Saborido, James Oyee, Vidhya Sagar Ramani

Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection

Hui-Fang Hung, Hsiu-Hsi Chen

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

Helen Dakin, Morris Sherman, Scott Fung, Carrie Fidler, Anthony Bentley